Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

Jean‐Jacques Kiladjian, Claire Harrison, Alessandro M. Vannucchi et al.|Blood|2014

Cited by 14